Graduate School of Biomedical Sciences Winter 2024


For the last decade, the Icahn School of Medicine at Mount Sinai has made tremendous investments in high-performance computing, big data analytics, and deep learning. As such, we were one of the first medical schools in the nation to create a department devoted to artificial intelligence (AI) and human health. Today, we are at the forefront of this rapidly evolving space.

The numerous research and educational initiatives in computing and big data analytics that span various departments and institutes at Icahn Mount Sinai, including those at the Graduate School of Biomedical Sciences, demonstrate our firm commitment to harnessing the power of these extraordinary tools to revolutionize scientific research, modernize biomedical education, and drive advances that enhance the well-being of patients and their families.

Still, if we are to sustain, nurture, and safely benefit from this revolution, our health care system will need to thoughtfully expand training at the crossroads of biomedical sciences and computational biology/AI technologies.

Over the past seven years, the Graduate School has established several educational programs to support a future workforce of biomedical researchers who are well-versed in these new technologies—master’s programs in Biomedical Data Science and Epidemiology, as well as a PhD concentration in Artificial Intelligence and Emerging Technologies in Medicine.

Additionally, we are expanding collaborative research opportunities for students and postdocs with several technical institutions with whom we are affiliated. This creates an “intelligent fabric” that infuses machine learning and AI-driven decision-making throughout the Mount Sinai Health System, New York City’s largest with eight hospital campuses.

Icahn Mount Sinai is a true research powerhouse. We are No. 13 in the nation among medical schools for National Institutes of Health funding—reaching $502.4 million in fiscal year 2023 (NIH Reporter), with research areas such as Neuroscience at No. 4; Genetics, No. 5; and Cell Biology, No. 6 (Blue Ridge Institute for Medical Research, fiscal year 2022). On the clinical front, we are No. 4 in Public Health funding, which greatly speaks both to our strength in this field and to the Graduate School’s robust Master of Public Health program.

We take enormous pride in being a forward-thinking and independent institution devoted to training the next generation of leaders in scientific and clinical discovery, innovation, education, health policy, clinical care, and advocacy—and always in a diverse, equitable, and inclusive learning environment.

Our Graduate School is a community like no other—richly diverse, creative, and profoundly collaborative. Read on to learn more about who we are and how we intend to redefine graduate education and training.


Marta Filizola, PhD

Marta Filizola, PhD

Dean of the Graduate School of Biomedical Sciences, the Sharon & Frederick A. Klingenstein/Nathan G. Kase, MD Professor of Pharmacological Sciences, Professor of Neuroscience, and Professor of Artificial Intelligence and Human Health